Literature DB >> 30887031

Drug Costs: What Can Infectious Diseases Physicians Do?

Shashi N Kapadia1, Roy M Gulick1.   

Abstract

Keywords:  Harvoni; Sovaldi; cost-benefit analysis; drug cost; generic Drugs; health care costs; health policy; linezolid; medical ethics; pharmacoeconomics; practice guidelines; prescription drugs; truvada

Mesh：

Substances：

Year:  2020        PMID： 30887031      PMCID： PMC7325612          DOI： 10.1093/infdis/jiz067

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  20 in total

1.  Illness and injury as contributors to bankruptcy.

Authors:  David U Himmelstein; Elizabeth Warren; Deborah Thorne; Steffie Woolhandler
Journal:  Health Aff (Millwood)       Date:  2005 Jan-Jun       Impact factor: 6.301

2.  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.

Authors:  Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Courtney Tyne; Douglas W Blayney; Diane Blum; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2015-06-22       Impact factor: 44.544

3.  Trading Bankruptcy for Health: A Discrete-Choice Experiment.

Authors:  Mark G Shrime; Milton C Weinstein; James K Hammitt; Jessica L Cohen; Joshua A Salomon
Journal:  Value Health       Date:  2017-09-01       Impact factor: 5.725

4.  Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.

Authors:  Mehdi Najafzadeh; Karin Andersson; William H Shrank; Alexis A Krumme; Olga S Matlin; Troyen Brennan; Jerry Avorn; Niteesh K Choudhry
Journal:  Ann Intern Med       Date:  2015-03-17       Impact factor: 25.391

5.  Barriers to patient-physician communication about out-of-pocket costs.

Authors:  G Caleb Alexander; Lawrence P Casalino; Chien-Wen Tseng; Diane McFadden; David O Meltzer
Journal:  J Gen Intern Med       Date:  2004-08       Impact factor: 5.128

6.  Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

Authors:  Vincent Lo Re; Charitha Gowda; Paul N Urick; Joshua T Halladay; Amanda Binkley; Dena M Carbonari; Kathryn Battista; Cassandra Peleckis; Jody Gilmore; Jason A Roy; Jalpa A Doshi; Peter P Reese; K Rajender Reddy; Jay R Kostman
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-05       Impact factor: 11.382

7.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Authors:  Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2018-07-24       Impact factor: 56.272

8.  High Generic Drug Prices and Market Competition: A Retrospective Cohort Study.

Authors:  Chintan V Dave; Aaron S Kesselheim; Erin R Fox; Peihua Qiu; Abraham Hartzema
Journal:  Ann Intern Med       Date:  2017-07-04       Impact factor: 25.391

9.  The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.

Authors:  Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim
Journal:  Ann Intern Med       Date:  2015-05-05       Impact factor: 51.598

10.  Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study.

Authors:  Charitha Gowda; Stephen Lott; Matthew Grigorian; Dena M Carbonari; M Elle Saine; Stacey Trooskin; Jason A Roy; Jay R Kostman; Paul Urick; Vincent Lo Re
Journal:  Open Forum Infect Dis       Date:  2018-06-07       Impact factor: 3.835
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.